Publications

Detailed Information

Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea`s general population

DC Field Value Language
dc.contributor.authorLee, Nam Young-
dc.contributor.authorKim, Se Hyun-
dc.contributor.authorCho, Belong-
dc.contributor.authorLee, Yeon Ji-
dc.contributor.authorKang, Ung Gu-
dc.contributor.authorAhn, Yong Min-
dc.contributor.authorKim, Yong Sik-
dc.contributor.authorChang, Jae Seung-
dc.date.accessioned2012-07-04T06:03:02Z-
dc.date.available2012-07-04T06:03:02Z-
dc.date.issued2010-10-01-
dc.identifier.citationPROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY; Vol.34 7; 1243-1249ko_KR
dc.identifier.issn0278-5846-
dc.identifier.urihttps://hdl.handle.net/10371/78422-
dc.description.abstractDespite growing concerns about the co-morbidity of metabolic syndrome (MetS) and bipolar disorder, few studies have been conducted on this topic in Asian populations This study examined Korean patients with bipolar disorder to assess its co-morbidity with MetS and to compare the prevalence of MetS in patients with medication for bipolar disorder with that of healthy patients We used cross-sectional data from the medical records of patients with bipolar disorder who presented to the psychiatric clinic in Seoul National University Hospital between June 2007 and June 2008. The control group, matched for age and gender, was randomly drawn from visitors to the Health Promotion Center at the same hospital during the same period We compared the prevalence of MetS between these two groups with independent sample t-tests and chi-squared tests We also calculated the indirectly standardized prevalence ratio (ISPR) with a standardization that used the Fourth Korean National Health and Nutrition Examination Survey (KNHNES. 2007) The prevalence of MetS in patients who took medication for bipolar disorder (N = 152) was 270%. 25.0% and 25 7%, based on the definitions of the American Heart Association and the National Heart, Lung and Blood Institute`s adaptation of the Adult Treatment Panel III (AHA), the National Cholesterol Education Program for Adult Treatment Panel III (ATPIII) and the International Diabetes Federation (IDF), respectively The present study determined that the prevalence of MetS was significantly higher in patients with bipolar disorder than in the control group, the odds ratios (OR) (95%CI) were 2.44 (1 35-4 40), 248 (1.34-459) and 257 (1.40-4.74), based on the definition of the ANA. ATPIII and IDF, respectively.The ISPR (95%CI) was 1.48(1 02-1 93), 1.54(1 05-2 03) and 1 98 (1 36-2 60). respectively Patients with medications for bipolar disorder showed a significantly higher prevalence of increased waist circumference, elevated triglycerides. and reduced HDL-cholesterol than the control group. The prevalence of MetS in patients taking medication for bipolar disorder was higher than that in the general population Obesity and dyslipidemia were particularly prevalent in patients with bipolar disorder (C) 2010 Elsevier Inc All rights reservedko_KR
dc.description.sponsorshipThis study was supported by National Research Foundation of
Korea Grant funded by the Korean Government (2009-0077030).
ko_KR
dc.language.isoenko_KR
dc.publisherPERGAMON-ELSEVIER SCIENCE LTDko_KR
dc.subjectMetabolic syndromeko_KR
dc.subjectBipolar disorderko_KR
dc.subjectControl groupko_KR
dc.subjectIndirectly standardized prevalence ratioko_KR
dc.subjectCross-sectionalko_KR
dc.titlePatients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea`s general populationko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이남영-
dc.contributor.AlternativeAuthor김세현-
dc.contributor.AlternativeAuthor조비룡-
dc.contributor.AlternativeAuthor이연지-
dc.contributor.AlternativeAuthor장재승-
dc.contributor.AlternativeAuthor강웅구-
dc.contributor.AlternativeAuthor김용식-
dc.contributor.AlternativeAuthor안용민-
dc.identifier.doi10.1016/j.pnpbp.2010.06.029-
dc.citation.journaltitlePROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY-
dc.description.citedreferenceMeyer JM, 2009, J CLIN PSYCHIAT, V70, P318-
dc.description.citedreferenceDe Hert M, 2009, WORLD PSYCHIATRY, V8, P15-
dc.description.citedreferenceCHANG HH, 2009, J AFFECT DISORD-
dc.description.citedreferenceCorrell CU, 2008, J CLIN PSYCHIAT, V69, P1948-
dc.description.citedreferenceCorrell CU, 2008, BIPOLAR DISORD, V10, P788, DOI 10.1111/j.1399-5618.2008.00625.x-
dc.description.citedreferenceDaumit GL, 2008, SCHIZOPHR RES, V105, P175, DOI 10.1016/j.schres.2008.07.006-
dc.description.citedreferenceAder M, 2008, J PSYCHIATR RES, V42, P1076, DOI 10.1016/j.jpsychires.2008.01.004-
dc.description.citedreferencevan Winkel R, 2008, J CLIN PSYCHIAT, V69, P1319-
dc.description.citedreferenceFiedorowicz JG, 2008, ANN CLIN PSYCHIATRY, V20, P131, DOI 10.1080/10401230802177722-
dc.description.citedreferenceSicras A, 2008, BIPOLAR DISORD, V10, P607-
dc.description.citedreferenceSalvi V, 2008, GEN HOSP PSYCHIAT, V30, P318, DOI 10.1016/j.genhosppsych.2008.04.009-
dc.description.citedreferenceFagiolini A, 2008, J CLIN PSYCHIAT, V69, P678-
dc.description.citedreferencevan Winkel R, 2008, BIPOLAR DISORD, V10, P342-
dc.description.citedreferenceSicras-Mainar A, 2008, EUR PSYCHIAT, V23, P100, DOI 10.1016/j.eurpsy.2007.07.005-
dc.description.citedreferencePark HS, 2008, OBES REV, V9, P104, DOI 10.1111/j.1467-789X.2007.00421.x-
dc.description.citedreferenceGarcia-Portilla MP, 2008, J AFFECT DISORDERS, V106, P197, DOI 10.1016/j.jad.2007.06.002-
dc.description.citedreferenceCardenas J, 2008, J AFFECT DISORDERS, V106, P91, DOI 10.1016/j.jad.2007.05.030-
dc.description.citedreferenceFagiolini A, 2008, CNS DRUGS, V22, P655-
dc.description.citedreferenceFAUCI AS, 2008, HARRISONS PRINCIPLES-
dc.description.citedreferenceKim B, 2008, J AFFECT DISORDERS, V105, P45, DOI 10.1016/j.jad.2007.04.006-
dc.description.citedreferenceNarisawa S, 2008, J EPIDEMIOL, V18, P37, DOI 10.2188/jea.18.37-
dc.description.citedreferenceMcIntyre RS, 2007, CURR OPIN PSYCHIATR, V20, P406-
dc.description.citedreferenceBirkenaes AB, 2007, J CLIN PSYCHIAT, V68, P917-
dc.description.citedreferenceYumru M, 2007, J AFFECT DISORDERS, V98, P247, DOI 10.1016/j.jad.2006.08.009-
dc.description.citedreferenceGuo JJ, 2006, J CLIN PSYCHIAT, V67, P1055-
dc.description.citedreferenceAlberti KGMM, 2006, DIABETIC MED, V23, P469-
dc.description.citedreferenceCorrell CU, 2006, J CLIN PSYCHIAT, V67, P575-
dc.description.citedreferenceDe Hert MA, 2006, SCHIZOPHR RES, V83, P87, DOI 10.1016/j.schres.2005.12.855-
dc.description.citedreferenceMcEvoy JP, 2005, SCHIZOPHR RES, V80, P19, DOI 10.1016/j.schres.2005.07.014-
dc.description.citedreferenceGrundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404-
dc.description.citedreferenceFagiolini A, 2005, BIPOLAR DISORD, V7, P424-
dc.description.citedreferenceLieberman JA, 2005, NEW ENGL J MED, V353, P1209-
dc.description.citedreferenceLim S, 2005, DIABETES CARE, V28, P1810-
dc.description.citedreferenceCOHN T, 2004, CAN J PSYCHIAT, V49, P753-
dc.description.citedreference2002, CIRCULATION, V106, P3143-
dc.description.citedreferenceJIN H, 2002, ANN CLIN PSYCHIAT, V14, P59-
dc.description.citedreferenceKoller E, 2001, AM J MED, V111, P716-
dc.description.citedreferenceWetterling T, 2001, DRUG SAFETY, V24, P59-
dc.description.citedreferenceHenderson DC, 2000, AM J PSYCHIAT, V157, P975, DOI 10.1176/appi.ajp.157.6.975-
dc.description.tc4-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share